NCT02569424

Brief Summary

There is no recommendation for the management of the positive end-expiratory pressure (PEEP) during setting of a central venous catheter (CVC) in a ventilated patient. Several non-randomized studies have investigated the cross-sectional area (AST) ultrasound minor axis for different pressure levels by evaluating a single vessel every time or by not displaying the right or left side in the evaluation. Another study showed that there could be unpredictable size differences between the 2 subclavian veins. In ventilated patient, the PEEP, which is intrathoracic, will result in a decrease of venous return and thus possibly a superior vena cava dilation, located outside the pleura, depending on their capacitance. Different pressure levels showed an increase of AST with the increase of intra-thoracic pressure on certain veins, in a heterogeneous and not randomized manner. The primary purpose of the study is to measure the effect of PEEP (0, 5, 10 or 15 cm H2O) and the patient's position (supine or Trendelenburg strict -15-20 °) on the cross-sectional area of the jugular and subclavian veins.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2015

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2015

Completed
23 days until next milestone

First Submitted

Initial submission to the registry

September 24, 2015

Completed
12 days until next milestone

First Posted

Study publicly available on registry

October 6, 2015

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

December 5, 2016

Status Verified

December 1, 2016

Enrollment Period

1.3 years

First QC Date

September 24, 2015

Last Update Submit

December 2, 2016

Conditions

Keywords

PEEP levelTrendelenburg positioncross-sectional area of the jugular and subclavian veinscentral venous catheter

Outcome Measures

Primary Outcomes (1)

  • The cross-sectional area of the jugular veins ( in cm2)

    The cross-sectional area of the jugular veins ( in cm2) at the end of the intervention

    at baseline

Secondary Outcomes (5)

  • The cross-sectional area of the subclavian veins ( in cm2)

    at baseline

  • The antero-posterior diameter of the jugular veins (in mm)

    at baseline

  • The antero-posterior diameter of the subclavian veins (in mm)

    at baseline

  • The distance between posterior and pleural lining of the jugular veins (in mm)

    at baseline

  • The distance between posterior and pleural lining of the subclavian veins (in mm)

    at baseline

Study Arms (1)

ventilated patients

EXPERIMENTAL

Patient's position (Supine or Trendelenburg strict -20°)

Behavioral: Patient's position

Interventions

Supine or Trendelenburg strict -20°)

ventilated patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Any patient ventilated in intensive care is eligible.
  • Age ≥ 18 years
  • Patient with stable hemodynamic status and Mean Blood Pressure (\< 65 mmHg)
  • Patient with registered social security number

You may not qualify if:

  • presence of a central line for more than 48 hours.
  • Anechoic patient (checked during echography screening)
  • History of cervical spine surgery.
  • IntraCranial HyperTension
  • patient in shock with hemodynamic instability and not stabilized
  • patient treated by noradrenaline \> 1 µg/kg/min
  • patient or relative's refusal
  • protected patients ≥ 18 years, minors, pregnant women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Clermont-Ferrand

Clermont-Ferrand, 63003, France

Location

Study Officials

  • Sébastien PERBET

    University Hospital, Clermont-Ferrand

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 24, 2015

First Posted

October 6, 2015

Study Start

September 1, 2015

Primary Completion

December 1, 2016

Study Completion

December 1, 2016

Last Updated

December 5, 2016

Record last verified: 2016-12

Locations